Hypertension

This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diurestics and renal denervation therapy.

Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be more than 750,000 patients annually worldwide

News | Hypertension

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

January 19, 2024 — Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk ...

January 19, 2024

Pulmonary arterial hypertension, a form of high blood pressure that occurs in the lungs, is a target of research by Cedars-Sinai investigators.

News | Hypertension

Unique Cell-based Approach for Pulmonary Arterial Hypertension Shown to Be Safe

December 13, 2023 —Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary ...

December 13, 2023

Dushani Ranasinghe, PhD, left, and Margaret Schwarz, MD, at Ranasinghe's graduation ceremony from the University of Notre Dame.

News | Hypertension

New Target Identified for Pulmonary Hypertension Treatment

December 7, 2023 — Indiana University School of Medicine researchers at the school’s South Bend regional campus, in ...

December 07, 2023

News | Cardiovascular Education

Minneapolis Heart Institute Foundation Research Advances Understanding of Health Equity and Outcomes in Fourth-Trimester Care for Women

December 4, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular ...

December 04, 2023

Approval is the culmination of ten years of clinical research and development of the Medtronic renal denervation technology

News | Renal Denervation

Medtronic Announces FDA Approval of Minimally Invasive Device to Treat Hypertension

November 20, 2023 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and ...

November 20, 2023

A groundbreaking advancement in the treatment of patients with uncontrolled hypertension (HTN) has been achieved with the recent U.S. Food & Drug Administration (FDA) approvals of two renal denervation (RDN) systems

News | FDA

Renal Denervation Systems Receive FDA Approval, Revolutionizing Treatment for Uncontrolled Hypertension

November 20, 2023 — A groundbreaking advancement in the treatment of patients with uncontrolled hypertension (HTN) has ...

November 20, 2023

Innovative new treatment option for patients with uncontrolled hypertension now available in the United States

News | Hypertension

Recor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy

November 15, 2023 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the first ...

November 15, 2023

Results of a randomized trial presented today at the American Heart Association’s Scientific Sessions 2023, AHA 2023, which compared the effects of high-sodium and low-sodium diets on blood pressure in adults, found that following a low-sodium diet significantly lowered blood pressure in 70%-75% of participants in as little as one week

News | AHA

Reducing Sodium Intake Significantly Lowered Blood Pressure in as Little as One Week, Reports AHA 2023 Late-Breaking Science Abstract

November 11, 2023 — Results of a randomized trial presented today at the American Heart Association’s Scientific ...

November 11, 2023

Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

News | FDA

First FDA Approval of Renal Denervation System to Treat Hypertension Announced by Recor Medical and Otsuka Medical Devices

November 8, 2023 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. has announced that the U ...

November 08, 2023

Smidt Heart Institute investigators say condition, apparent resistant hypertension, is common, and a particular medication may get patients’ disease under control

News | Hypertension

Novel Study Deepens Knowledge of Treatment-Resistant Hypertension

September 22, 2023 — For many patients with hypertension--an elevated blood pressure that can lead to stroke or heart ...

September 22, 2023

IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients

News | Hypertension

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients

September 20, 2023 — Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to ...

September 20, 2023

All pregnant people should have their blood pressure measured at each prenatal visit

News | Hypertension

Task Force Issues Final Recommendation Statement on Screening for Hypertensive Disorders of Pregnancy

September 20, 2023 — The U.S. Preventive Services Task Force (Task Force) published a final recommendation statement on ...

September 20, 2023

The analysis of the health records found that, on average, participants’ systolic blood pressure increased by up to 1.7 mm Hg in the winter months compared to the summer months

News | Hypertension

Study from AHA Hypertension Scientific Sessions Reports on Cold Weather’s Impact on Treating High Blood Pressure

September 13, 2023 — Blood pressure among patients diagnosed with hypertension appeared to slightly increase, and rates ...

September 13, 2023

Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN).

News | Cardiovascular Clinical Studies

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

September 12, 2023 — Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of ...

September 12, 2023

Recipient of the Harry Goldblatt Award for New Investigators from the American Heart Association’s 2023 Hypertension Council

News | Hypertension

Faulkner to be Honored by American Heart Association

September 7, 2023 —Jessica Faulkner, PhD, a physiologist whose research is focused on sex differences in cardiovascular ...

September 07, 2023